Despite the potentially lower expression levels, CCL19 performed as the best APC-binding molecule when combined with 5 CT26-predicted neoepitopes and, therefore, was selected to further develop an APC-targeted TCV for cancer neoepitopes. This evidence concerns the gene APC and cancer.